Company

Recce Pharmaceuticals Ltd

ASX:RCE

Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.

169 stories · page 5 of 9

Pharma & Biotech

Recce Pharmaceuticals given safety committee green light to expand diabetic foot infection trial

By Proactive 26/02/2024

Pharma & Biotech

Recce Pharmaceuticals in MoU with Indonesian biotech to accelerate clinical development of anti-infectives

By Proactive 06/02/2024

Pharma & Biotech

Recce Pharmaceuticals to expand R327 trials for diabetic foot infection after positive human efficacy data

By Proactive 18/01/2024

Pharma & Biotech

Recce Pharmaceuticals higher on positive efficacy data in Murdoch Children’s Research Institute UTI study

By Proactive 28/12/2023

Pharma & Biotech

Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs

By Proactive 18/12/2023

Pharma & Biotech

Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program

By Proactive 14/12/2023

Pharma & Biotech

Recce Pharmaceuticals achieves strong anti-bacterial effect against deadly Neisseria gonorrhoeae pathogen in animal model

By Proactive 14/12/2023

Pharma & Biotech

Recce Pharmaceuticals secures Canadian Patent for anti-infectives

By Proactive 23/11/2023

Pharma & Biotech

Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial

By Proactive 07/11/2023

Pharma & Biotech

Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum

By Proactive 31/10/2023

Pharma & Biotech

Recce Pharmaceuticals welcomes safety committee approval of faster infusion rate for RECCE® 327 in urosepsis clinical trial

By Proactive 24/10/2023

Pharma & Biotech

Recce Pharmaceuticals raises further funds to progress trials from entitlement shortfall

By Proactive 06/10/2023

Pharma & Biotech

Recce Pharmaceuticals demonstrates R327 safety profile at faster infusion rate

By Proactive 22/09/2023

Pharma & Biotech

Recce Pharmaceuticals secures $8 million in placement, launches $3 million entitlement offer

By Proactive 11/09/2023

Pharma & Biotech

Recce Pharmaceuticals’ RECCE® issued registered trademark in Vietnam

By Proactive 06/09/2023

Pharma & Biotech

Recce Pharmaceuticals makes strides with R327G drug in multiple antibiotic-resistant infection cases

By Proactive 01/09/2023

Pharma & Biotech

Antimicrobial resistance and the coming plague

By Proactive 29/08/2023

Pharma & Biotech

Recce Pharmaceuticals has next cohort dosing of R327 approved; paves way for UTI treatment

By Proactive 28/08/2023

Pharma & Biotech

Recce Pharmaceuticals has patients dosed in Phase I/II diabetic foot infection clinical trial

By Proactive 22/08/2023

Pharma & Biotech

Recce Pharmaceuticals successfully treats deadly burn infections in Phase I/II clinical trial

By Proactive 21/08/2023